Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kyle J. Ernzen"'
Publikováno v:
Antibody Therapeutics
Background The Epidermal Growth Factor Receptor (EGFR) ligand, Amphiregulin (AREG), is a key proliferative effector of estrogen receptor signaling in breast cancer and also plays a role in other malignancies. AREG is a single-pass transmembrane prote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24c208f763b75e8c516510beda7951bf
http://europepmc.org/articles/PMC8643873
http://europepmc.org/articles/PMC8643873
Autor:
Kyle J. Ernzen, Amanda R. Panfil
Publikováno v:
Bioscience reports. 42(3)
Human T-cell leukemia virus type 1 (HTLV-1) is the only identified oncogenic human retrovirus. HTLV-1 infects approximately 5–10 million people worldwide and is the infectious cause of adult T-cell leukemia/lymphoma (ATL) and several chronic inflam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0c7b2f9e3e7021fc0105d802ea764c0
https://pubmed.ncbi.nlm.nih.gov/35169839
https://pubmed.ncbi.nlm.nih.gov/35169839
The Epidermal Growth Factor Receptor ligand, Amphiregulin, is a key proliferative effector of estrogen receptor signaling in breast cancer and also plays a role in other malignancies. Amphiregulin is a single-pass transmembrane protein proteolyticall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77bda3d75dbff3350ab0d97e630bbaa4
https://doi.org/10.1101/2021.07.07.451518
https://doi.org/10.1101/2021.07.07.451518
Publikováno v:
Cancer Research. 82:331-331
The EGFR ligand, Amphiregulin, is a key proliferative effector of estrogen receptor signaling in breast cancer and also plays a role in other malignancies. Amphiregulin is a single-pass transmembrane protein proteolytically processed by TACE/ADAM17 t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6816e46cf85328d04eb5ab98912a53a
https://doi.org/10.1158/1538-7445.am2022-331
https://doi.org/10.1158/1538-7445.am2022-331
Publikováno v:
Molecular Cancer Therapeutics. 20:P184-P184
The Epidermal Growth Factor Receptor ligand, Amphiregulin, is a key proliferative effector of estrogen receptor signaling in breast cancer and also plays a role in other malignancies. Amphiregulin is a single-pass transmembrane protein proteolyticall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dfb3574873e53a096065f95647420c7
https://doi.org/10.1158/1535-7163.targ-21-p184
https://doi.org/10.1158/1535-7163.targ-21-p184
Autor:
Paraic A. Kenny, Kristopher A. Lofgren, Kyle J Ernzen, Sreeja Sreekumar, Grzegorz T. Gurda, David R. Meier, Craig S. Richmond, Jake A. Deviley, Benjamin M. Parsons
Publikováno v:
Cancer Research. 79:1317-1317
Crizotinib is FDA approved in lung cancers with alterations in MET, ROS1 or ALK. Alterations in these genes are also reported in breast cancer, but are very rare and not routinely evaluated. Here we describe two heavily pre-treated patients with meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a23320ca0bed8b8ec268400b3678a204
https://doi.org/10.1158/1538-7445.am2019-1317
https://doi.org/10.1158/1538-7445.am2019-1317
Publikováno v:
Cancer Research. 78:2873-2873
Prostate cancer (PCa) is the second most common cancer among men and is the third leading cause of cancer-related death in the United States. In 2017 alone, an estimated 161,360 men will be diagnosed with PCa and approximately 26,730 deaths will resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac9e27cc821e7143102f860037b31d99
https://doi.org/10.1158/1538-7445.am2018-2873
https://doi.org/10.1158/1538-7445.am2018-2873